Appia Bio
Irving Weissman, MD, is director of the Stanford Institute for Stem Cell Biology and Regenerative Medicine, Professor of Clinical Investigation in Cancer Research, Professor of Developmental Biology, and, by courtesy, of Biology. As the first scientist to identify and isolate mammalian blood-forming stem cells in mice, Dr. Weissman is an expert in stem cell biology and hematopoiesis, cancer stem cells, and macrophage immune checkpoints. His group has successfully defined the stages of development that occur between stems cells and mature progeny. Dr. Weissman’s lab was the first to identify, prospectively isolate, and transplant human and murine HSCs. He earned an MD from Stanford University and a BS from Montana State College.
This person is not in the org chart
This person is not in any offices
Appia Bio
Appia Bio is an early-stage biotechnology company based in Los Angeles, California. Founded in 2020, Appia Bio is focused on discovering and developing engineered allogeneic cell therapies across a broad array of indications with a scalable technology platform that increases access for patients. With its ACUA (Appia Cells Utilized for Allogeneic) technology platform, Appia Bio leverages the biology of lymphocyte development with chimeric antigen receptor (CAR) and T-cell receptor (TCR) gene engineering to generate CAR-engineered invariant natural killer T (CAR-iNKT) cell subtypes from hematopoietic stem cells (HSCs).